Nevro’s HFX Offers Durable Benefit In People Suffering Diabetic Pain

 
• By Reed Miller

New 24-month data from the SENZA-PDN trial, presented at the American Diabetes Society conference in New Orleans, provides more support for HFX 10 kHz as a reliable therapy for people with painful diabetic neuropathy.

Nevro's Senza Omnia HFX Spinal Cord Stimulation System
Nevro's Senza Omnia Implantable Spinal Cord Stimulator • Source: Nevro

More from Clinical Trials

More from R&D